Lumicell Announces Accomplished Healthcare Leader as New Member to Board of Directors

Independent director, Jim Alecxih, Chief Executive Officer of DH Medical joins Lumicell’s Board of Directors NEWTON, Mass., Jan. 6, 2025 – Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is pleased to announce the appointment of Jim Alecxih to its Board of Directors. The Lumicell Board has appointed Mr. Jim Alecxih as a new independent director. Currently serving as Chief Executive Officer of DH Medical, Alecxih leads a team focused on advancements in imaging, video transmission, and signal processing technologies. He previously held executive leadership roles at other market-leading companies, including Intuitive Surgical, where he spearheaded exponential revenue growth of robotic-assisted surgical systems. “We’re excited to welcome Jim to our Board of Directors. His extensive commercial and operational experience, along with a proven track record of success, will be invaluable to Lumicell,” said Howard Hechler, Chief Executive Officer of Lumicell. “Jim’s deep experience in the healthcare industry and diagnostic imaging aligns seamlessly with Lumicell’s mission to advance cancer detection across the continuum of solid tumors and improve surgical outcomes.” “I’m honored to join Lumicell’s Board of Directors at such a pivotal moment in the company’s history, as it is initiating its U.S. commercial launch. I look forward to contributing to the continued development and research of its platform technology,” said Alecxih. “Lumicell’s innovative fluorescence-guided imaging technology fills critical gaps in cancer care, offering the ability to detect cancer that would otherwise remain undetected.” About Lumicell Inc. Lumicell is a privately held life sciences company revolutionizing the intraoperative detection of cancer with its real-time fluorescence imaging technology. Lumicell’s proprietary technology is FDA-approved for use in the treatment of breast cancer and is also being explored for further development across a wide variety of solid tumor indications. For more information, please visit www.Lumicell.com and www.LearnAboutLumicell.com. Follow the company on Facebook, X, and LinkedIn. This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this press release reflect Lumicell’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions, and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the regulatory process to approve pharmaceutical drugs or medical devices. Media inquiries – [email protected] Manage Cookie Consent To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent

The release as fetched from its publisher. lumicell.com ↗